Canada-based pharmaceutical company ESSA Pharma Inc (NASDAQ:EPIX) on Monday issued a statement clarifying the period of due bill trading in connection with its USD80m return of capital distribution.

The company confirmed that shareholders received approximately USD1.6910318 per common share on 22 August 2025, in connection with the wind-up of its business following a transaction with XenoTherapeutics Inc, a non-profit biotechnology company.

In its 14 August 2025 release, Essa Pharma incorrectly stated that common shares would trade with due bills through 25 August 2025. The correct period was from 19 August 2025 through 22 August 2025.

Shares began trading on an ex-dividend basis on 25 August 2025, the first business day after the payment date. The company emphasised that no due bills were attached to trades on that date.